Molecular Simulation-Based Investigation of Highly Potent Natural Products to Abrogate Formation of the nsp10–nsp16 Complex of SARS-CoV-2SARS-CoV-2의 nsp10–nsp16 복합체 형성을 폐지하기 위한 매우 강력한 천연물에 대한 분자 시뮬레이션 기반 조사Article Published on 2021-04-142022-09-10 Journal: Biomolecules [Category] SARS, 치료기술, 치료제, [키워드] addition African antiviral drugs best binding affinity binding energy calculated complex Compound compounds conformational database demonstrated disrupt drug interaction Drug interactions feature Formation functional genkwanin inhibit innate immune system Interaction Interface residues investigation life cycle molecular molecular dynamic simulation molecular dynamics Molecular mechanics molecules mRNA natural natural product non-structural protein North nsp10 nsp10–nsp16 complex path potent product risk SARS-CoV-2 SARS-CoV-2 life cycle screened selected Side effects stability stable complex surface area Viral [DOI] 10.3390/biom11040573 PMC 바로가기 [Article Type] Article
Tackling Immune Pathogenesis of COVID-19 through Molecular PharmaceuticsPerspective Published on 2021-04-052022-10-28 Journal: Pharmaceutics [Category] COVID-19, [키워드] Anakinra anti-inflammatory agent anti-inflammatory strategy Antiviral benefit clinical study Clinical use Coronavirus disease-19 COVID-19 COVID-19 patients drug Drug discovery Drug interactions effective effective therapy Efficacy immunomodulatory increased risk Infection inflammatory pathway Injury Intervention knowledge Medicines molecular molecular pharmaceutics pandemic pathway Perspective Pharmaceutics Prevent Repurposed drug required Safe tested therapy treat treatment approaches tryptophan metabolites [DOI] 10.3390/pharmaceutics13040494 PMC 바로가기 [Article Type] Perspective
Potential Drug Interactions of Repurposed COVID-19 Drugs with Lung Cancer Pharmacotherapies재활용된 COVID-19 약물과 폐암 약물 요법의 잠재적 약물 상호 작용Review Published on 2021-04-012022-08-31 Journal: Archives of medical research [Category] MERS, SARS, 신약개발, 치료제, [키워드] adverse outcomes anti-cancer treatment Azithromycin cancer patient Care ceftriaxone Chemotherapy Chloroquine Comorbidity Complication concomitant treatment concomitant treatments COVID-19 COVID-19 infection COVID-19 pandemic Dexamethasone dissemination drug Drug interactions drug-drug interaction Drug-drug interactions Famotidine Favipiravir Healthcare professional healthcare professionals history of smoking Hydroxychloroquine identification identify Immunosuppression information kinase inhibitors Lopinavir Lopinavir/ritonavir lung cancer lung cancer patient lung cancer patients malignancy management medication medications occur oseltamivir outcome Patient pharmacotherapy Potential Prophylactic proportion QT prolongation rationale receiving recent Remdesivir reported Reporting Repurposed drug ribavirin risk risk factor Ritonavir sarilumab severity smoking Tocilizumab tyrosine tyrosine kinase inhibitors umifenovir with COVID-19 [DOI] 10.1016/j.arcmed.2020.11.006 PMC 바로가기 [Article Type] Review
Clinically Significant Drug Interactions Between Psychotropic Agents and Repurposed COVID-19 Therapies향정신성 제제와 용도 변경 COVID-19 치료제 간의 임상적으로 중요한 약물 상호작용Review Published on 2021-04-012022-09-11 Journal: CNS drugs [Category] MERS, 신약개발, 유전자 메커니즘, 치료제, [키워드] acting agent clinically concomitant use COVID-19 COVID-19 therapy cytochrome P450 drug drug interaction Drug interactions drug-drug interaction expected infected with COVID-19 Interaction management Manifestations mechanism P450 Patient pharmacogenetic pharmacokinetic polymorphism Polymorphisms Psychiatric psychiatric disorder Psychiatric disorders Psychotropic psychotropic agent psychotropic agents Psychotropic medication psychotropic medications raise recommendation responsible resulting severity severity of illness Significant Stage subject synergistic Therapies therapy Toxicity [DOI] 10.1007/s40263-021-00811-2 PMC 바로가기 [Article Type] Review
Neurological Consequences of SARS-CoV-2 Infection and Concurrence of Treatment-Induced Neuropsychiatric Adverse Events in COVID-19 Patients: Navigating the UnchartedMolecular Biosciences Published on 2021-02-182022-10-31 Journal: Frontiers in Molecular Biosciences [Category] COVID-19, [키워드] ACE2 acute respiratory syndrome Adverse adverse event Affect angiotensin-converting enzyme 2 anti-retroviral drug Antibiotics bind Central nervous system Chloroquine clinically CNS Combination Complication concurrence consequence contributing to coronavirus Corticosteroid COVID - 19 COVID-19 Critical Dexamethasone Diseases dissemination Drug interactions drug-drug interaction Encephalitis Encephalopathy event Evidence Favipiravir Guillain-barrè syndrome help hematogenous Hemorrhagic highlight human cell Hydroxychloroquine Hypogeusia Hyposmia immune responses include induce Injury leukoencephalopathy Lopinavir-ritonavir mechanism mechanisms medication Meningitis morbidity and mortality nervous system neurologic neurologic manifestations Neurological disorder neurological manifestation neuronal Neuropsychiatric neuropsychiatric adverse effects neurotropic neurotropism off-label outcome pandemic pathophysiological Pathways Perspective Pneumonia Post-infection potential therapy Psychiatric disorders psychological Impact receptor Remdesivir Repurposed drug researchers Respiratory complications SARS – CoV – 2 SARS-CoV-2 SARS-COV-2 infection stroke syndrome therapeutic potential thrombosis Tocilizumab Uncharted venous virus virus infection with COVID-19 [DOI] 10.3389/fmolb.2021.627723 PMC 바로가기 [Article Type] Molecular Biosciences
Opportunities, Challenges and Pitfalls of Using Cannabidiol as an Adjuvant Drug in COVID-19 †COVID-19에서 보조 약물로 칸나비디올을 사용할 때의 기회, 도전 및 함정 †Review Published on 2021-02-172022-09-10 Journal: International Journal of Molecular Sciences [Category] 치료제, [키워드] ACE2 acting acute respiratory syndrome acute respiratory syndrome coronavirus adjuvant administration antinociceptive anxiolytic cannabidiol cannabis challenge Clinical studies clinical study coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 demonstrated disadvantage Disadvantages disease diseases of the respiratory system downregulate drug drug interaction Drug interactions Effect Effectiveness IMPROVE Infection inhibit SARS-CoV-2 lead life limit multiple organ dysfunction organ dysfunction patients with COVID-19 Post-traumatic stress symptoms preclinical studies preclinical study Protein Quality of life Replication respiratory Respiratory disease Respiratory system responsible SARS-CoV-2 SARS-CoV-2 replication severe acute respiratory syndrome Coronavirus severe acute respiratory syndrome coronavirus 2 shown Side effect Side effects Treatment treatment of COVID-19 turn Viral viral entry [DOI] 10.3390/ijms22041986 PMC 바로가기 [Article Type] Review
Investigational Treatments for COVID-19 may Increase Ventricular Arrhythmia Risk Through Drug InteractionsCOVID-19에 대한 조사 치료는 약물 상호 작용을 통해 심실 부정맥 위험을 증가시킬 수 있습니다Article Published on 2021-02-012022-09-11 Journal: CPT: pharmacometrics & systems pharmacology [Category] 치료제, [키워드] action potential Analysis Arrhythmias Azithromycin cardiac adverse event cardiac adverse events cardiac electrophysiology caused cellular Chloroquine Combination combination therapy coronavirus disease Coronavirus disease 2019 COVID-19 disease drug drug combination drug combinations Drug interactions drugs Effect Factor greater healthy individual healthy individuals heart disease heart failure increase Isolation lead Lopinavir mathematical men molecular Myocyte Patient patient group pharmacokinetics potential benefits predict predicted QT prolongation Quantitative reported risk Ritonavir Sex Simulation statistical analysis susceptible Therapies treat Treatment ventricular ventricular arrhythmias women [DOI] 10.1002/psp4.12573 PMC 바로가기 [Article Type] Article
Safety of hydroxychloroquine and darunavir or lopinavir in COVID-19 infectionCOVID-19 감염에서 하이드록시클로로퀸과 다루나비르 또는 로피나비르의 안전성Observational Study Published on 2021-01-192022-09-11 Journal: Journal of Antimicrobial Chemotherapy [Category] 임상, 치료제, [키워드] age approach cardiovascular disease chronic cardiovascular clinical evaluations Clinical practice combination therapy Concentration condition COVID-19 COVID-19 infection COVID-19 pneumonia darunavir disease Drug interactions during treatment ECG abnormalities ECG abnormality eight electrocardiogram Electrocardiograms examined Hydroxychloroquine hypertension IMPROVE initial kidney Kidney failure Lopinavir Lopinavir/ritonavir males median median age Observational cohort study outcome Patient patients died patients hospitalized pharmacokinetics Pneumonia reversed Ritonavir Safety Seven significantly suggested the patient therapy treated Treatment with COVID-19 [DOI] 10.1093/jac/dkaa441 PMC 바로가기 [Article Type] Observational Study
IDentif . AI : Rapidly optimizing combination therapy design against severe Acute Respiratory Syndrome Coronavirus 2 (SARS‐Cov‐2) with digital drug developmentResearch Report Published on 2020-12-012022-10-27 Journal: Bioengineering & Translational Medicine [Category] COVID-19, [키워드] acute respiratory syndrome approach artificial intelligence clinical trial clinically collected Combination combination therapy combinatory treatment coronavirus coronavirus 2 COVID‐19 Digital medicine dosages drug combination Drug development drug interaction Drug interactions Efficacy experimental validation Hydroxychloroquine in vitro Infectious disease Live virus magnitude Outbreaks outcome outcomes overcome Patient platform reduction in Remdesivir representing respiratory Ritonavir SARS‐CoV‐2 SARS‐CoV‐2 therapy trials [DOI] 10.1002/btm2.10196 PMC 바로가기 [Article Type] Research Report
Antiviral drugs for influenza for 2020-2021Article Published on 2020-11-022023-07-12 Journal: The Medical letter on drugs and therapeutics [Category] SARS, [키워드] adverse effects amantadine antiviral drugs baloxavir coronavirus dosage Drug interactions Efficacy FluMist Influenza influenza vaccine lactation neuraminidase inhibitors oseltamivir Peramivir Pregnancy Rapivab Relenza Rimantadine Safety Tamiflu Xofluza zanamivir